相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Jung Hun Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer - A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
Peter C. Thuss-Patience et al.
EUROPEAN JOURNAL OF CANCER (2011)
Second-line chemotherapy for gastric cancer: a new issue lies ahead in global trials
Hiroya Takiuchi
GASTRIC CANCER (2011)
Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
Y. -K. Kang et al.
ANNALS OF ONCOLOGY (2009)
Is there a role for second-line chemotherapy in advanced gastric cancer?
Robert Wesolowski et al.
LANCET ONCOLOGY (2009)
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane
Sun Jin Sym et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
V. Catalano et al.
BRITISH JOURNAL OF CANCER (2008)
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
Wasaburo Koizumi et al.
LANCET ONCOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Disparities in gastric cancer chemotherapy between the East and West
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes
SH Park et al.
ANTI-CANCER DRUGS (2005)
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
ST Kim et al.
BRITISH JOURNAL OF CANCER (2005)
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma
L Assersohn et al.
ANNALS OF ONCOLOGY (2004)
Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy
JH Chun et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
LB Saltz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
